{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:58:12Z","timestamp":1792058292406,"version":"4.4.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1097\/01.jcp.0000264995.31771.05","type":"journal-article","created":{"date-parts":[[2007,7,9]],"date-time":"2007-07-09T04:05:22Z","timestamp":1183953922000},"page":"407-408","source":"Crossref","is-referenced-by-count":14,"title":["Exacerbation of Myoclonus by Memantine in a Patient With Alzheimer Disease"],"prefix":"10.1097","volume":"27","author":[{"given":"Sokratis G.","family":"Papageorgiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Kontaxis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Antelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kalfakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210128","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1503\/cmaj.1060168","article-title":"Use of memantine to treat Alzheimer's disease.","volume":"175","author":"Gauthier","year":"2006","journal-title":"CMAJ"},{"key":"R2-21-20210128","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0028-3908(99)00019-2","article-title":"Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data.","volume":"38","author":"Parsons","year":"1999","journal-title":"Neuropharmacology"},{"key":"R3-21-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1527-3458.2003.tb00254.x","article-title":"The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.","volume":"9","author":"Rogawski","year":"2003","journal-title":"CNS Drug Rev"},{"key":"R4-21-20210128","first-page":"S7","article-title":"Anatomy and physiology of glutamate in the CNS.","volume":"44","author":"Greenamyre","year":"1994","journal-title":"Neurology"},{"key":"R5-21-20210128","first-page":"210","article-title":"Aggressive course of disease in dementia. Alzhheimer's & Dementia.","volume":"2","author":"Gauthier","year":"2006","journal-title":""},{"key":"R6-21-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1353-8020(02)00054-8","article-title":"Myoclonus and neurodegenerative disease-what's in a name?","volume":"9","author":"Caviness","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"key":"R7-21-20210128","first-page":"399","article-title":"Myoclonus in Alzheimer's disease and minipolymyoclonus.","volume":"43","author":"Hallett","year":"1986","journal-title":"Adv Neurol"},{"key":"R8-21-20210128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00023210-200418020-00003","article-title":"Drug-induced myoclonus: frequency, mechanisms and management.","volume":"18","author":"Jimenez-Jimenez","year":"2004","journal-title":"CNS Drugs"},{"key":"R9-21-20210128","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome.","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"key":"R10-21-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.wnf.0000165351.10841.fa","article-title":"Olanzapine-induced myoclonic status.","volume":"28","author":"Camacho","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"R11-21-20210128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/01.jcp.0000219927.49799.c0","article-title":"Combination therapy of lamotrigine and escitalopram may cause myoclonus.","volume":"26","author":"Rosenhagen","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R12-21-20210128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(03)00502-7","article-title":"Treatment of Alzheimer's disease: current status and new perspectives.","volume":"2","author":"Scarpini","year":"2003","journal-title":"Lancet Neurol"},{"key":"R13-21-20210128","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease.","volume":"348","author":"Reisberg","year":"2003","journal-title":"N Engl J Med"},{"key":"R14-21-20210128","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0","article-title":"Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine).","volume":"14","author":"Winblad","year":"1999","journal-title":"Int J Geriatr Psychiatry"},{"key":"R16-21-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jama.291.3.317","article-title":"Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.","volume":"291","author":"Tariot","year":"2004","journal-title":"JAMA"},{"key":"R17-21-20210128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02253435","article-title":"Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats?-case of amantadine and memantine.","volume":"7","author":"Danysz","year":"1994","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"R18-21-20210128","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1212\/WNL.56.2.279","article-title":"Amantadine-induced cortical myoclonus.","volume":"56","author":"Matsunaga","year":"2001","journal-title":"Neurology"},{"key":"R19-21-20210128","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.brainresbull.2005.12.001","article-title":"Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: a microdialysis study.","volume":"69","author":"Shearman","year":"2006","journal-title":"Brain Res Bull"},{"key":"R20-21-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0304-3940(01)01872-9","article-title":"The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2\/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner.","volume":"306","author":"Rammes","year":"2001","journal-title":"Neurosci Lett"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-200708000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:48:24Z","timestamp":1786034904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-200708000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jcp.0000264995.31771.05","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}